Avadel Pharmaceuticals plc (NASDAQ: AVDL) is 5.23% higher on its value in year-to-date trading and has touched a low of $9.41 and a high of $19.09 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AVDL stock was last observed hovering at around $11.00 in the last trading session, with the day’s gains setting it 0.06%.
Currently trading at $11.06, the stock is 6.13% and -6.11% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.33 million and changing 0.55% at the moment leaves the stock -24.21% off its SMA200. AVDL registered -22.49% loss for a year compared to 6-month loss of -25.17%. The firm has a 50-day simple moving average (SMA 50) of $11.7796 and a 200-day simple moving average (SMA200) of $14.59245.
The stock witnessed a 11.27% gain in the last 1 month and extending the period to 3 months gives it a -13.66%, and is 4.24% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.97% over the week and 4.42% over the month.
Avadel Pharmaceuticals plc (AVDL) has around 154 employees, a market worth around $1.07B and $138.16M in sales. Fwd P/E is 22.94. Profit margin for the company is -52.53%. Distance from 52-week low is 17.53% and -42.06% from its 52-week high. The company has generated returns on investments over the last 12 months (-65.79%).
The EPS is expected to grow by 75.72% this year.
Avadel Pharmaceuticals plc (AVDL) Top Institutional Holders
233.0 institutions hold shares in Avadel Pharmaceuticals plc (AVDL), with institutional investors hold 84.58% of the company’s shares. The shares outstanding are 96.34M, and float is at 88.15M with Short Float at 13.08%. Institutions hold 80.54% of the Float.
The top institutional shareholder in the company is VIVO CAPITAL, LLC with over 3.97 million shares valued at $55.85 million. The investor’s holdings represent 4.332% of the AVDL Shares outstanding. As of 2024-06-30, the second largest holder is TRI LOCUM PARTNERS LP with 1.19 million shares valued at $16.72 million to account for 1.2973 of the shares outstanding. The other top investors are BIOIMPACT CAPITAL LLC which holds 0.78 million shares representing 0.8542% and valued at over $11.01 million, while KNOLL CAPITAL MANAGEMENT, LLC holds 0.6544 of the shares totaling 0.6 million with a market value of $8.44 million.
Avadel Pharmaceuticals plc (AVDL) Insider Activity
The most recent transaction is an insider purchase by MCHUGH THOMAS S, the company’s Chief Financial Officer. SEC filings show that MCHUGH THOMAS S bought 2,300 shares of the company’s common stock on Dec 13 ’24 at a price of $10.44 per share for a total of $24019.0. Following the purchase, the insider now owns 87800.0 shares.
Avadel Pharmaceuticals plc disclosed in a document filed with the SEC on Dec 11 ’24 that MCHUGH THOMAS S (Chief Financial Officer) bought a total of 5,000 shares of the company’s common stock. The trade occurred on Dec 11 ’24 and was made at $10.49 per share for $52432.0. Following the transaction, the insider now directly holds 85500.0 shares of the AVDL stock.
Still, SEC filings show that on Dec 06 ’24, Divis Gregory J (Chief Executive Officer) acquired 9,598 shares at an average price of $9.98 for $95759.0. The insider now directly holds 9,598 shares of Avadel Pharmaceuticals plc (AVDL).
